




YEAR END REPORT
JAN - DEC 2022



CONTINUED STRONG ORDER INTAKE AND IMPROVED CASHFLOW

- Continued overall growth for the year and continued strong performance for the hospital as well as strategic alliances business areas.
- Multiple larger hospital orders in both the Asia Pacific region and Americas region in the quarter conclude a year with strong growth of the order intake for our hospital business area to 71.2 MSEK compared to 24.3 MSEK for previous year.
- Our focus on our operational efficiency is showing in the quarter where we generate positive net results, positive EPS and an improved cashflow from operations as well as an improved cash position.

FOURTH QUARTER (OCTOBER- DECEMBER 2022)

- Order intake amounted to 90.3 (73.8) MSEK.
- Orderbook by the end of the period was 126.0 (87.1) MSEK.
- Net sales amounted to 68.7 (67.7) MSEK.
- Earnings before depreciation and amortization (EBITDA) totaled 11.5 (12.0) MSEK.
- Net income for the period amounted to 2.1 (-4.2) MSEK.
- Earnings per share (EPS) was 0.08 (-0.17) SEK.
- Cash flow from operating activities totaled 26.0 (7.4) MSEK.

FULL YEAR (JANUARY- DECEMBER 2022)

- Order intake amounted to 252.2 (205.6) MSEK.
- Net sales amounted to 218.0 (185.1) MSEK.
- Earnings before depreciation and amortization (EBITDA) totaled -3.9 (2.5) MSEK.
- Net income for the period amounted to -30.7 (-29.2) MSEK.
- Earnings per share (EPS) was -1.22 (-1.18) SEK.
- Cash flow from operating activities totaled 14.9 (-5.1) MSEK.

COMMENTS BY THE CEO

The fourth quarter of 2022 concluded the year as a year of continued growth, driven by strong growth from both the hospital and strategic alliances business areas but also partly fueled by exchange rate. For the fourth quarter we are pleased to see the initial effects on cost saving activities implemented during the third quarter. We have reduced external costs, improved our cash position, increased operational cashflow and also a small but positive EPS.

For the full year we have delivered a growth in net sales of almost 18% (including currency effects) and we reached a new all-time high of 218.0 MSEK for net sales in 2022. At the same time, we have increased our order intake from 205 MSEK to 252 (23%) and our orderbook at the end of 2022 was 126 (87) MSEK, an increase of 45%.

We are also pleased to see that, despite improvement during 2021 we have continued to improve our margins for 2022 resulting in an average gross margin of 85.5% up from 81.0% in 2021. This is driven by price adjustments but also our focus on product mix and margin on deal levels. Currency exchange rates also have a positive effect on margins.

We are excited with the development of our new businesses where Ankyras and our Spanish organization recently filed the FDA application for regulatory approval in the United States. We also continue to develop the market for our physical simulation solutions (Vascular Simulations acquired 2020) and we can clearly see how our expanded range within the vertical of the image guided therapy arena resonates with the market as well as with our clients.

REGIONS, BUSINESS AREAS AND SEGMENTS

Our American region has delivered on par with last year from an order intake point of view in SEK. However in local currency there was a decline compared to previous year. This is a combination of the effect of a very strong 2021 for our MDI business, which is largely US dominated, and our MDI customers phasing issues relating to logistic, supply and regulatory. On a positive note we can see the Hospital business in US is delivering at record level with several larger deals at the end of the year. We see a large demand from the US MDI sector, and we have a positive outlook for 2023.

Our APAC Region had delivered growth in orders up to 40% despite pandemic related issues in the first half of the year. The hospital and strategic alliances business has of course been positively impacted by both the Siemens Robotics order in Q1 then followed by the announced CMEA order in Q4 for 1.1MUUSD but also generally strong demand across the region.

The EMEA region has performed the strongest of our three regions with growth exceeding 40% across all three business areas while the most significant growth came from the hospital sector which grew more than 2x compared to the previous year.



Generally, our assessment is that 2022 marks a return to normal for the hospital business as well as the hospital business related to our strategic alliance's partners. Our MDI business has been strong throughout the pandemic but in our mind, negatively impacted by factors already mentioned earlier. With the outcome of 2022 we are also back to a more normal and healthy distribution between the business areas where our MDI is 60%, hospital 28% and strategic alliances 12% of our total order intake. During the pandemic our MDI business dominated our order intake with a share of over 80% in 2021.

MARKET ASSESSMENT

We have experienced strong demand for all our products, business areas and regions in 2022. Even if the outcome in the Americas region, mainly linked to the medical device industry (MDI), was not to our expectation, our order-book is continuously improving. We can also see that the stricter European medical device regulation causes a move to consolidation of the industry business to the North American region. The rebound of the hospital market is highly promising, and we see demand levels on and above 2019 before the pandemic and we believe this demand will continue into 2023.

CONT. MARKET ASSESSMENT

So far, we have seen limited impact from a weaker economy, and we continue to see a strong demand for both our and our clients' products and services.

However, during the ongoing turbulence in the world, we have seen multiple situations during the last year where we or our clients have been impacted by logistic or supply-related issues. This could, in turn risk to delay demand for our products and services. So far, we have been able to manage these situations without a larger impact on our business.

The possible downturn as well as continuous inflation pressures are risks that we need to mitigate to the best of our ability. However, overall, we believe the business climate for Mentice is positive.

SUMMARY

During 2022 Mentice has passed several milestones in achieving net sales above 200 MSEK and an order intake of 252 MSEK. In addition, our acquisition of Ankyras strengthens our strategy to become a leader in image guided therapy.

We can see indications that our effort on costs and margins are delivering improved earnings and cash flow, however we want to see further margin and cash flow improvements prior to initiating growth of organization again.

Gothenburg in February 2023,

Göran Malmberg

CEO, Mentice AB (publ)

KEY FIGURES

	Oct-Dec 2022	Oct-Dec 2021	Change	Jan-Dec 2022	Jan-Dec 2021	Change	RTM*
Order intake, MSEK	90.3	73.8	22.3%	252.2	205.6	22.7%	252.2
whereof Medical Device In-dustry (MDI)	51.3	59.8	-14.3%	151.6	167.3	-9.4%	151.6
whereof Healthcare systems	34.0	7.1	378.4%	71.4	24.4	193.0%	71.4
whereof Strategic Alliances	5.0	6.9	-27.0%	29.3	13.9	110.3%	29.3
Order book (end of period). MSEK	126.0	87.1	44.7%	126.0	87.1	44.7%	126.0
Net sales. MSEK	68.7	67.7	1.4%	218.0	185.1	17.8%	218.0
Sales. MSEK	66.0	70.9	-7.0%	220.3	190.2	15.8%	220.3
Gross margin. %	89.4%	79.0%		85.4%	81.0%		85.4%
Operating income before depreciation (EBITDA). MSEK	11.5	12.0		-3.9	2.5		-3.9
EBITDA-margin. %	16.8%	17.8%		-1.8%	1.3%		-1.8%
Income before tax (EBIT). MSEK	7.0	3.1		-24.0	-21.3		-24.0
Income for the period. MSEK	2.1	-4.2		-30.7	-29.2		-30.7
Earnings per share. SEK	0.08	-0.17		-1.22	-1.18		-1.22
Cash-flow from operations. MSEK	26.0	7.4		14.9	-5.1		14.9
Cash at the end of the period. MSEK	47.3	12.7		47.3	12.7		47.3
Equity/Asset ratio. %	48.8%	52.3%		48.8%	52.3%		48.8%
Number of employees at the end of the period	122	104		122	104		122
FTE for the quarter and full year**	113.8	101.3		113.8	101.3		113.8

*RTM = rolling twelve months

** FTE – Full time equivalents

FINANCIAL PERFORMANCE


ORDER INTAKE PER BUSINESS AREA

Order intake during the fourth quarter increased by 22.3% to 90.3 (73.8) MSEK. For the Medical Device Industry, we experience a decline of 14.3% compared to last quarter 2021. We see this as a result of a very strong fourth quarter in 2021 combined with a delay of orders moving into 2023.


Order intake for the full year increased to 252.2 (205.6) MSEK an increase by 22.7% year on year, whereof 16% currency, 5% acquired and 1.7% organic growth. This was mainly due to the lack of growth for MDI, despite strong recovery on the health-care system and strategic alliances businesses. This also renders a more balanced distribution between the business areas both in the quarter and full year as shown in the pie charts below.

Order intake per business area TSEK	Oct-Dec 2022	Oct-Dec 2021	Variance	Jan-Dec 2022	Jan-Dec 2021	Variance
Medical Device Industry	51,270	59,811	-14.3%	151,558	167,338	-9.4%
Healthcare Systems	33,986	7,104	378.9%	71,357	24,358	192.9%
Strategic Alliances	5,045	6,906	-27.0%	29,333	13,948	110.3%
Total	90,301	73,822	22.3%	252,248	205,645	22.9%


Oct-Dec 2022




Jan-Dec 2022




Oct-Dec 2021



Jan-Dec 2021



FINANCIAL PERFORMANCE, CONT.




ORDER INTAKE PER REGION

Order intake per region shows continuous strong growth both in EMEA and APAC in the quarter and full year numbers. The Americas region taking main impact of the slower MDI business due to our customers issues relating to logistics, supply and regulatory, we see no growth in the fourth quarter. It was slightly above last year including impact with exchange rates for USD to SEK. Several orders moved between the years into 2023 especially in the Americas region.

Order intake per region TSEK	Oct-Dec 2022	Oct-Dec 2021	Variance	Jan-Dec 2022	Jan-Dec 2021	Variance
EMEA	31,840	23,979	32,8%	77,172	51,599	49,6%
APAC	23,305	11,757	98,2%	71,029	51,112	39,0%
Americas	35,155	38,086	-7,7%	104,047	102,933	1,1%
Total	90,301	73,822	22,3%	252,248	205,645	22,7%

FINANCIAL PERFORMANCE, CONT.



ORDERBOOK

The orderbook closed at 126.0 (87.1) MSEK by the end of the year, which represents a growth of 44.7%. The orderbook represents orders received but not yet delivered. Out of the total orderbook per December 31 2022, 24.3 MSEK is for systems and software perpetual, and 15.1 MSEK for software subscription that will be delivered and recognized as net sales in 2023 and 37.8 MSEK for 2024 and onwards. 35.3 MSEK refers to deliveries of rental and support agreements that are to be delivered and recognized as revenue in the coming three years and the remaining 13.4 MSEK is development contracts with customers that will be delivered during 2023.

NET SALES

The group's net sales consist of sales of systems and software, service and support, and sales from consultancy assignments referred to as development contracts. Software licenses sold as perpetual are recognized as net sales at delivery, together with hardware, while software licenses sold as a subscription model are recognized as net sales over time, and sales in this dimension are referred to as Segments.

Mentice also reports sales figures for three geographic markets: EMEA (Europe, Middle East and Africa), APAC (Asia and the Asian Pacific Region) and Americas (North, Central and South America) and for three business areas, Medical Device Industry, Healthcare and Strategic Alliances.


FINANCIAL PERFORMANCE, CONT.

NET SALES PER BUSINESS AREA

Of the net sales for the fourth quarter 48.2 (51.8) MSEK came from the business area Medical Device Industry, 10.1 (9.5) MSEK came from Healthcare Systems and 10.4 (6.4) MSEK from the business area Strategic Alliances. We continue to see the shift of mix towards more Healthcare systems and Strategic Alliances vs Medical Device Industry sales as the pandemic releases its grip on the hospital market.

Of the net sales for the full year 160.4 (139.2) MSEK came from the business area Medical Device Industry, 37.9 (31.6) MSEK came from Healthcare Systems and 19.6 (14.3) MSEK from the business area Strategic Alliances, Total growth for the year is 17.8% whereof 8.4% is the impact of currency fluctuations.

Net sales per business area TSEK	Oct-Dec 2022	Oct-Dec 2021	Variance	Jan-Dec 2022	Jan-Dec 2021	Variance
Medical Device Industry	48,225	51,829	-7.0%	160,425	139,161	15.3%
Healthcare Systems	10,056	9,461	6.3%	37,908	31,576	20.1%
Strategic Alliances	10,422	6,398	62.9%	19,621	14,327	36.9%
Total	68,704	67,688	1.5%	217,954	185,064	17.8%




FINANCIAL PERFORMANCE, CONT.

NET SALES PER REGION

Net sales grew in EMEA and Americas but decreased in APAC, mainly due to the slow recovery from the pandemic especially in China. In EMEA the net sales growth comes from the strong recovery of the healthcare market and in the Americas the main impact that explains the growth in the fourth quarter is currency.

Full year net sales grew fast in EMEA and this is clearly connected to the fast recovery of the Healthcare market in this region. APAC delivered similar levels compared to last year clearly negatively impacted by the delay of the completion of the Corindus contract moving further into 2023 and again also for the full year the main impact for Americas was currency.

Net sales per region TSEK	Oct-Dec 2022	Oct-Dec 2021	Variance	Jan-Dec 2022	Jan-Dec 2021	Variance
EMEA	16,727	15,397	8.6%	62,886	41,301	52.3%
APAC	11,970	15,765	-24.1%	48,970	50,561	-3.1%
Americas	40,006	36,526	9.5%	106,099	93,203	13.8%
Total	68,704	67,688	1.5%	217,954	185,064	17.8%



FINANCIAL PERFORMANCE, CONT.

NET SALES PER BUSINESS SEGMENT

Out of the net sales for the fourth quarter 21.4 (32.0) MSEK came from system sales for customer's capex, where net sales is recognized in full upon delivery of the system. Another 5.5 (2.8) MSEK came from recurring system sales where net sales are recognized over time for rental period of the systems. 9.6 (11.9) of total net sales came from software licenses sales for customer's capex, where net sales are recognized upon delivery of software together with the system.

Furthermore, recurring software licenses amounted to 10.5 (6.1) MSEK and refers to software licenses sold as subscription model where net sales is recognized over time. Both Accessories & spare parts as well as service net sales are recognized at delivery and came in at 21.8 (14.9) MSEK. Net sales grew 17.8%. All business segments grew except Software licenses Customer's capex, where our subscription model is adopted well by the market.

Net sales per business segment TSEK	Oct-Dec 2022	Oct-Dec 2021	Variance	Jan-Dec 2022	Jan-Dec 2021	Variance
System sales, Customer's CAPEX	21,392	32,027	-33.2%	83,268	78,398	6.2%
System sales, recurring	5,469	2,751	98.8%	17,584	7,056	149.2%
Software licenses, Customer's CAPEX	9,556	11,915	-19.8%	28,108	37,739	-25.5%
Software licenses, recurring	10,452	6,130	70.5%	34,122	19,267	77.1%
Accessories & spare parts	5,258	5,873	-10.5%	17,498	16,834	3.9%
Service	16,577	8,992	84.4%	37,374	25,770	45.0%
Total	68,704	67,688	1.5%	217,954	185,064	17.8%

FINANCIAL PERFORMANCE, CONT.

OTHER INCOME

Other income was -2.7 (3.3) MSEK for the quarter and 2.4 (5.2) MSEK for the full year. During the second quarter the company obtained a 1.2 MSEK grant from Swedfund. During the fourth quarter, a one-time currency impact in the amount of 1.8 MSEK was due to a reclassification of realized exchange loss on inter-company transactions from cost of material to other income. The rest is related to exchange rate variances in operating assets and liabilities in foreign currencies.

GROSS PROFIT AND GROSS MARGIN

The gross profit for the fourth quarter was 61.4 (53.4) MSEK and 186.0 (149.9) MSEK for the full year. Gross margin was at 89.4% for the fourth quarter, compared to 79.0% for the same period in prior year. The gross margin for the full year was 85.4% compared to 81.0% last year.

Gross margin is in general impacted by the mix of products sold and the level of support and service as well as the level of net sales from software licenses versus systems. For the fourth quarter we add to the above-mentioned impacts also the effect of currency, mainly purchases of goods and materials in SEK and sales in USD and EUR.

OPERATING RESULT (EBITDA) AND OPERATING MARGIN

Operating income before depreciation, EBITDA, was 11.5 (12.0) MSEK, for the fourth quarter. This corresponds to an operating margin of 16.8 (17.8) % for the fourth quarter. The main impact on the operating result for the quarter was the increase in total operating costs of 9.3%.

EBITDA for the full year was -3.9 (2.5) MSEK with operating margins of -1.8 (1.3) %. The main impact on the operating result is higher operating cost level for 2022 of 27%.

OTHER EXTERNAL COSTS

Other external costs totaled -7.4 (-14.8) MSEK during the fourth quarter, which equals a decrease of 50.4% compared to the same period last year. The decrease was mainly due to the impact of efficiency and cost reduction activities in the quarter. In addition a one-time impact in the amount of 1.9 MSEK was due to a reclassification from other external costs to personnel costs.

For the full year, other external costs increased 12.2% to -52.9 (-47.2) MSEK, mainly through activities reducing use of consultants' vs own employees, containment of travel for the latter part of the year and legal cost in relation to directed issues of shares and the acquisition.



FINANCIAL PERFORMANCE, CONT.

PERSONNEL COSTS

Personnel costs during the fourth quarter increased 33,2% to -39.8 (-29.9) MSEK. For the full year personnel costs came in at 139.4 (105.4) MSEK, an increase of 32.2%.

The increase in both the full year and the quarter was driven from increased volume related commission, moving consultants to employees, increased number of personnel, salary increase and lower capitalization of salary costs to development.

Personnel costs included capitalized costs for development with 1.1 (1.6) MSEK for the fourth quarter and 5.6 (8.3) MSEK for the full year. The total number of employees at the end of the quarter was 122 (104).

CAPITALIZED EXPENSES FOR DEVELOPMENT COSTS

Capitalized expenses for development costs during the fourth quarter totaled 1.3 (2.4) MSEK and for the full year 7.5 (16.5) MSEK and was mainly related to several ongoing projects. The capitalization is accounted for as income to external costs if the original cost is for consultants for the standard development and in personnel costs if the original cost is for own employees.

FINANCIAL ITEMS

Net financial items for the fourth quarter totaled 0.4 (-0.9) MSEK and for the full year -0.1 (-1.5) MSEK and was mainly related to exchange rate variances.

The net financial items for the year included -1.2 (-0.4) MSEK of interest expense on lease liabilities. in accordance with IFRS 16.

INCOME BEFORE TAX. NET RESULT FOR THE PERIOD AND EARNINGS PER SHARE

Tax on income for the quarter was -4.9 (-7.3) MSEK, mainly due to deferred tax on amortization of asset goodwill in the parent company. Net income for the period was 2.1 (-4.2) MSEK. Earnings per share was 0.08 (-0.17) SEK for the fourth quarter.

For the full year tax on income for the period came in at -6.6 (-7.9) MSEK and net income for the period was -30.7 (-29.2) MSEK and earnings per share was -1.22 (-1.18) SEK.

CASH FLOW

Cash flow from operations before changes in working capital was 11.1 (11.3) MSEK for the fourth quarter and for the full year -5.8 (0.7) MSEK. Cash flow from changes in working capital for the quarter was 14.9 MSEK compared to -4.0 MSEK same quarter last year. The changes in working capital in the fourth quarter were mainly attributable to a decrease in receivables generating 4.1 MSEK 2022 compared to -23.1 MSEK 2021. The change in working capital for the full year was 20.7 (-5.8) MSEK driven from lower increase in receivables -2.3 vs 39.4 MSEK last year. The cash flow from operating activities was 26.0 (7,4) MSEK in the fourth quarter and 14.9 (-5.1) MSEK for the full year.

Despite the higher net sales and the increase in accounts receivables overall we have been able to reduce the oldest overdue receivables with 13 MSEK in the quarter.

The cash flow for the year was affected in the second quarter by directed issue of shares which generated 56.5 MSEK in positive cash flow net of transactions costs of 3.5 MSEK from financing activities and paid the first payment of -19.2 MSEK for the assets in Ankyras.

CASH AND FINANCIAL POSITION

Cash at the end of the period was 47.3 (12.7) MSEK. The group's total assets amounted to 333.0. (261.9) MSEK. IFRS 16 affected total assets by 14.4 (14.1) MSEK. Accounts receivable increased during the period to 85.6 (68.3) MSEK. Inventories amounted to 16.9 (9.2) MSEK. Current liabilities were 153.7 (110.3) MSEK excluding current leasing liability. The carrying amounts of financial assets and liabilities are considered to correspond essentially to fair value.

The company has an overdraft facility of 20 MSEK.

FINANCIAL PERFORMANCE, CONT.

INVESTMENTS

Investments during the fourth quarter totaled -6.2 (-5.1) MSEK. Of the investments -1.3 (-2.8) MSEK refers to the capitalization of development costs. The remainder refers to investments in tangible assets relating to new hardware devices for internal use and customer rentals.

As at the balance sheet date 31 December 2022, the group carried a payable in the amount of 9.0 MSEK for the remaining purchase price for the assets in Ankyras.

ANKYRAS AQUISITION

On the 30th of June the acquisition of the assets related to the software solution Ankyras from the Spanish corporation Galgo Medical SL was completed. The purchase price of 2.775 MEUR or 29 MSEK at exchange rate of 9th of June. This total price has now been reduced to 2.610 MEUR due to performance-related price adjustments. The first part of the purchase price 1.8 MEUR was paid on 30th of June and the second contingent payment of 0.56 MEUR was paid in January 2023. The last contingent payment of 0.25 MEUR is due in July 2023. The acquisition is related to precision medicine software solutions for the area of minimally invasive neuro interventional therapies, specifically for planning of aneurysm treatment in the brain.

The full purchase price allocation is preliminary based on estimates of the earn-out components and indicates allocation of 1,549 MEUR for patents, 0.499 MEUR for trademark and the remaining 0.572 MEUR in goodwill.

PARENT COMPANY

The parent company is an operating company. Net sales for the parent company amounted to 135.1 (132.7) MSEK for the full year. The income for the year corresponds largely to the sales within EMEA and APAC, the development department, and the head office in Sweden. The net income for the period was -32.8 (-31.3) MSEK, impacted by the 10.1 MSEK profit liquidating the group company in Switzerland.

SHARE CAPITAL

The total number of shares as of December 31, 2022 after the direct issue of shares were 25,568,850 (24,764,261) and the share capital was SEK 1,278 million. All shares are ordinary shares with equal voting value. The shares have a face value of SEK 0.05.

DISPUTES

The group has no current disputes.

TRANSACTIONS WITH RELATED PARTIES

Board member Denis Gestin has on a consulting basis acted as an advisor to the company in connection with customer related activities within the medical device industry. During the period January through December 2022 Gestin received 1.0 (0.6) MSEK.

Above transaction were conducted based on market value.

THE PURPOSE OF MENTICE

The purpose of Mentice solutions is to support the health-care professionals in their mission to; ensure all patients have an optimal outcome, improve cost-effectiveness, and generally, offer opportunities for the healthcare sector to better utilize its resources.

RISKS

Important risks and uncertainties for the group are primarily related to commercial customers and suppliers related to their supply and security in the implementation of new medical equipment. The financial risks lie in the global operations that the company operates.

This affects changes in exchange rates and interest rates, as well as liquidity, financing, and credit. Currency risk also arises when translating foreign net assets and earnings into Swedish kronor. Mentice overall goal is to avoid as far as possible financial risk taking, which can arise through changes in exchange rates, interest rates and market prices, as well as liquidity, financing, and credit risks. Exchange rate risk is divided into translation exposure and transaction exposure. Translation exposure refers to the exposure of net assets for foreign subsidiaries. Transaction exposure refers to the risks associated to purchases and net sales in foreign currency.

The group's external sales are made in the currencies EUR, GBP and USD. In the parent company, 75% (83%) of the external sales are in EUR, and most of the operating costs are in SEK. Net sales and cost in the US subsidiary are exclusively conducted in USD. For more information about the company's risks, see the board of directors' report in the annual report for 2021.

THE SHARE AND OWNERSHIP

Mentice AB (publ.) shares are traded on Nasdaq First North Growth Market since June 18, 2019 under MNTC. According to Euroclear's official register of shareholders, Mentice had a total of 1.669 shareholders by December 31, 2022. FNCA is the company's certified advisor.

Largest shareholders (source Euroclear 2022-12-31) Name	Number of shares	Shareholding in %
Karin Howell-Bidermann	8 690 980	34.0%
Bure Equity AB (publ)	3 761 659	14.7%
Handelsbanken Microcap Sverige	1 930 000	7.6%
Fjärde AP fonden	1 664 804	6.5%
Medical Simulation Corporation	1 191 074	4.8%
Berenberg Funds	932 391	3.7%
TIN Fonder	812 847	3.2%
Göran Malmberg	711 670	2.8%
Andra AP Fonden	446 620	1.8%
Avanza Pension	373 186	1.5%
10 largest shareholders total	20 515 231	80,2%
Others	5 053 619	19.8%
Total number of shares	25 568 850	

The information regarding shareholders has earlier only been taken from Euroclear and due to this some owners has been clustered into custodians without the correct breakout.

EXAMINATION BY THE AUDITORS

This report has not been a subject to a review by the company's auditors.

FINANCIAL REPORTS

Interim reports and other financial reports are available on the company's website. www.mentice.com.

AFFIRMATION



Mentice AB (publ)'s Board of Directors and CEO hereby assure that this interim report gives a true and fair view of the Group's business, financial position and performance and describe the essential risks and uncertainty factors that the company and the companies which are part of the Group are subjected to. In the event of any discrepancies between the English and Swedish versions of the report, the Swedish version shall prevail.

Gothenburg, February 2nd, 2023

Mentice AB (publ)

Magnus Nilsson	Chairman of the Board
Lawrence D. Howell	Board member
David J. Ballard	Board member
Denis Gestin	Board member
Gösta Johannesson	Board member
Johann Koss	Board member
Eola Änggård Runsten	Board member
Göran Malmberg	CEO



CONSOLIDATED INCOME STATEMENT



TSEK	Oct-Dec 2022	Oct-Dec 2021	Full year 2022	Full year 2021
Net sales	68,658	67,688	217,954	185,064
Other income	-2,705	3,284	2,370	5,155
	65,953	70,972	220,324	190,219
Raw materials and consumables used	-6,413	-14,072	-29,013	-34,954
Depreciation of rented assets	-888	-194	-2,904	-194
Other external costs	-7,353	-14,819	-52,925	-47,191
Personnel costs	-39,768	-29,863	-139,405	-105,426
Depreciation of tangible assets	-2,104	-2,870	-8,952	-9,959
Amortization and write-down of intangible assets	-2,825	-5,135	-11,077	-12,217
	-59,351	-66,871	-244,276	-209,941
Operating profit (EBIT)	6,602	4,019	-23,952	-19,722
Financial income	1,095	331	1,285	4
Financial expenses	-679	-1,275	-1,368	-1,553
Net financial items	416	-944	-83	-1,549
Earnings before tax (EBT)	7,018	3,075	-24,035	-21,271
Tax	-4,875	-7,273	-6,630	-7,920
Net result for the year	2,143	-4,198	-30,665	-29,191
Net result for the year attributable to:				
Shareholders parent company	2,143	-4,198	-30,665	-29,191
Earnings per share				
Basic (SEK)	0.08	-0.17	-1.22	-1.18
Diluted (SEK)	0.08	-0.17	-1.22	-1.18

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

TSEK	Oct-Dec 2022	Oct-Dec 2021	Full year 2022	Full year 2021
Net result for the year	2,143	-4,198	-30,665	-29,191
Other comprehensive income				
Items that will not be reclassified to profit or loss				
Items that may be reclassified to profit or loss				
Translation difference on translation of foreign operations	-3,741	1,734	-46	2,827
Other comprehensive income for the year. net of tax	-3,741	1,734	-46	2,827
Total comprehensive income for the year	-1,598	-2,464	-30,711	-26,364

CONSOLIDATED BALANCE SHEET



TSEK	31 December 2022	30 December 2021
Assets		
Goodwill	48,070	42,291
Patents	32,618	17,945
Trademarks	5,443	-
Internally developed intangible assets	44,285	45,766
Tangible assets	13,500	14,091
Rights-of-use assets	14,442	14,062
Deferred tax assets	9,777	13,966
Total non-current assets	168,135	148,121
Inventories	16,861	9,195
Accounts receivables	85,582	68,324
Prepaid costs and accrued income	9,858	17,895
Other receivables	5,255	5,672
Cash and cash equivalents	47,285	12,697
Total current assets	164,841	113,783
Total assets	332,976	261,904
Equity and liabilities		
Share capital	1,278	1,238
Other paid in capital	201,169	144,760
Retained earnings	-39,812	-9,111
Total equity attributable to parent company shareholders	162,635	136,887
Long term liabilities		
Leasing liabilities long-term	8,875	10,086
Total long-term liabilities	8,875	10,086
Accounts payable	14,231	8,997
Tax liabilities	99	319
Other liabilities	3,554	3,602
Current leasing liability	7,800	4,618
Accrued expenses and deferred income	135,782	97,395
Total current liabilities	161,466	114,931
Total equity and liabilities	332,976	261,904

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY



TSEK	Share Capital	Other Paid in Capital	Translation reserve	Retained Earnings	Total equity
At 1 January 2021	1,236	144,760	-1,919	19,174	163,251
Transactions with owners in their capacity as owners					
Issue of shares	2			-2	0
Profit for the year				-29,191	-29,191
Other comprehensive income for the year			2,827		2 827
Total comprehensive income for the period			2,827	-29,193	-26 364
Closing balance at 31 December 2021	1,238	144,760	908	-10,019	136,887
At 1 January 2022	1,238	144,760	908	-10,019	136,887
Transactions with owners in their capacity as owners					
Issue of shares	40	56,460			56,500
Payment of share options		-41			-41
Profit for the year				-30,665	-30,665
Other comprehensive income for the year		-10	-1,278	1,242	-46
Total comprehensive income for the year		-10	-1,278	-29,423	-30,711
Closing balance at 31 December 2022	1,278	201,169	-370	-39,442	162,635

CONSOLIDATED STATEMENT OF CASH FLOWS



TSEK	Oct - Dec 2022	Oct - Dec 2021	Full year 2022	Full year 2021
Operating activities				
Earnings before tax	7,018	3,075	-24,035	-21,271
Adjustment for non-cash items	4,364	8,320	19,113	22,367
Income tax paid	-315	-54	-871	-434
Cash flow from operating activities before changes in working capital	11,067	11,341	-5,793	662
Change in trade receivables and other current assets	4,143	-23,113	-2,279	-39,425
Change in inventories	-5,502	-2,038	-6,953	-3,138
Change in trade payables and other current liabilities	16,285	21,185	29,933	36,771
Change in working capital	14,926	-3,966	20,701	-5,792
Cash flow from operating activities	25,993	7,375	14,908	-5,130
Investing activities				
Acquisitions of tangible assets	-4,887	-2,327	-5,526	-9,049
Capitalisation of internally developed intangible assets	-1,318	-2,758	-7,528	-16,853
Acquisition of business, net cash effect			-19,224	
Cash flow from investing activities	-6,205	-5,085	-32,278	-25,902
Financing activities				
Payment of share options	-12		-41	
Proceeds from issue of share capital			60,000	
Payment of transaction costs			-3,500	
Amortization of lease liability	-2,223	-1,289	-7,468	-5,783
Cash flow from financing activities	-2,235	-1,289	48,991	-5,783
Cash flow for the period	17,553	1,001	31,621	-36,815
Opening cash balance	27,525	11,360	12,697	48,753
Translation difference on cash and cash-equivalents	2,207	336	2,967	759
Cash and bank balances at year-end	47,285	12,697	47,285	12,697

PARENT COMPANY INCOME STATEMENT



TSEK	Oct-Dec 2022	Oct-Dec 2021	Full year 2022	Full year 2021
Net sales	39,409	56,026	135,105	132,723
Capitalised expense for development	1,318	2,758	7,528	16,456
Other income	1,383	3,789	11,389	5,159
	42,110	62,573	154,022	154,338
Raw materials and consumables used	2,003	-10,032	-40,365	-23,618
Other external costs	-6,333	-21,651	-40,048	-67,068
Personnel costs	-25,034	-19,439	-87,432	-75,776
Depreciation of tangible assets	-311	-235	-1,088	-881
Amortization and write-down of intangible assets	-5,746	-13,904	-20,799	-20,840
Exchange losses on operating receivables and liabilities	-4,833	0	-7,219	0
	-40,253	-65,261	-196,951	-188,183
Operating profit (EBIT)	1,857	-3,085	-42,929	-33,845
Financial income	1,034	9,343	15,752	9,600
Financial expenses	217	-1,437	-4,269	-1,836
Net financial items	1,251	7,906	11,483	7,764
Result after financial items	3,108	4,821	-31,446	-26,081
Earnings before tax (EBT)	3,108	4,821	-31,446	-26,081
Tax	-1,389	-5,194	-1,389	-5,194
Net result for the year	1,719	-373	-32,835	-31,275

PARENT COMPANY BALANCE SHEET



TSEK	31 December 2022	31 December 2021
Assets		
Intangible and tangible assets		
Goodwill	30,552	34,093
Patents	33,288	19,016
Trademarks	5,442	-
Internally developed in-tangible assets	44,285	45,766
Tangible assets	3,482	3,158
Financial assets		
Shares in group companies	19,705	41,656
Receivables from group companies	10,213	13,476
Deferred tax assets	6,615	7,966
Total non-current assets	153,582	165,132
Inventories	10,104	6,541
Accounts receivables	50,087	35,400
Current receivables from group companies	2,701	-
Prepaid costs and accrued income	7,923	6,887
Other receivables	4,768	15,075
Cash and cash equivalents	36,419	4,968
Total current assets	112,001	68,871
Total assets	265,583	234,003
Equity and liabilities		
Restricted equity		
Share capital	1,278	1,238
Fund for development costs	48,468	52,914
Non-restricted equity		
Other paid in capital	201,169	144,750
Retained earnings	-62,145	-35,316
Net result for the year	-32,835	-31,275
Other paid in capital		
Total equity	155,935	132,311
Long term liabilities		
Liabilities to group companies	970	31,449
Total long-term liabilities	970	31,449
Accounts payable	9,383	7,978
Tax liabilities	79	-
Current liabilities to group companies	2,068	-
Other liabilities	1,778	3,805
Accrued expenses and de-ferred Income	95,370	58,460
Total current liabilities	108,678	70,243
Total equity and liabilities	265,583	234,003

PARENT COMPANY STATEMENT OF CHANGES IN EQUITY

TSEK	Restricted equity		Non-restricted equity	Retained earnings	Net result for the year	Total equity
	Share capital	Fund for development costs	Share premium reserve			
At 1 January 2021	1,236	45,750	144,760	-11,058	-17,096	163,592
Proposed appropriation of profits				-17,096	17,096	0
Transactions with owners in their capacity as owners						
Issue of shares	2			-2		0
Payment of share options						
Profit for the year		7,164	-10	-7,160	-31,275	-31 281
Other comprehensive income for the year						
Total comprehensive income for the year					-31,275	-31,275
Closing balance at 31 December 2021	1,238	52,914	144,750	-35,316	-31,275	132,311
At 1 January 2022	1,238	52,914	144,750	-35,316	-31,275	132,311
Proposed appropriation of profits				-31,275	31,275	0
Transactions with owners in their capacity as owners						
Issue of shares	40		56,460			56,500
Payment of share options			-41			-41
Profit for the year		-4,446		4,446	-32,835	-32,835
Other comprehensive income for the year						
Total comprehensive income for the year					-32,835	-32,835
Closing balance at 31 December 2022	1,278	48,468	201,169	-62,145	-32,835	155,935



NOTES



ACCOUNTING POLICIES

Mentice applies International Financial Reporting Standards (IFRS) as adopted by the EU. This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act.

The parent company's interim report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. Accounting for Legal Entities. issued by the Swedish Financial Reporting Board.

The accounting policies applied correspond to those of the previous financial year, as described in the annual report for 2021.

This is a change since earlier years and quarters where we were referring to our business areas as segments – see more information on page 28.

- System - sales and rental revenues including accessories and spare parts from hardware
- Software licenses - sales of licenses both perpetual and subscription model
- Service - sales of support, development, and other service contracts

BUSINESS SEGMENTS

Mentice started to report business segments in accordance with IFRS 8 for the first time in the annual report for 2021. Mentice's business is divided into three business segments, which reflect the group's operations, financial management and management structure. These three business segments are System, Software licenses and Service and we also added accessories and spare parts separately within the System group

We also report the net sales divided into for Capex - capital expenditure and recurring revenue and gross profit for these segments. The capital expenditure we refer to is our customer's point of view.

First half TSEK	System sales				Software licenses		Service		Total Group	
	System sales		Accessories & spareparts		Software licenses		Service			
	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Sales for capital expenditure	83,268	78,398	17,498	16,834	28,108	37,739	37,374	25,770	166,249	158,741
Recurring revenue	17,584	7,056	-	-	34,122	19,267	-	-	51,706	26,323
Total	100,852	85,454	17,498	16,834	62,230	57,005	37,374	25,770	217,954	185,064
Raw materials and consumables used	-25,944	-22,227	-5,754	-7,920	-	-	-219	-1,374	-31,917	-35,148
Gross profit	74,908	63,227	11,744	8,915	62,230	57,005	37,155	24,396	186,037	149,916
Gross profit %	74.3%	74.0%	67.1%	53.0%	100%	100%	99.4%	94.7%	85.4%	81.0%

Based on what has been mentioned above, note 3 from the annual report of 2021 will be adjusted according to the table above. See page 28.

NOTES, CONT.

BASES OF VALUATION APPLIED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

Assets and liabilities are recognized at historical cost with the exception of currency derivatives, which are measured at fair value. As per December 31, 2022, the total actual value of forward contracts was 0,04 (0) MSEK.

ASSESSMENTS AND ESTIMATES IN THE FINANCIAL STATEMENTS

Preparation of the financial statements in compliance with IFRS requires the company's management to make assessments, estimates and assumptions that affect the application of the accounting policies and the carrying amounts of assets, liabilities, income, and expenses. Actual outcomes may deviate from these estimates and assessments. Assumptions are reviewed on a regular basis. Changes to estimates are recognized in the period when the change is made if the change affects only that period, or in the period when the change is made and future periods if the change affects both the current period and future periods.

ADJUSTMENTS, ROUNDING

Some of the financial information provided in this report has been rounded, which may affect the totals in the tables.

FINANCIAL INSTRUMENTS, CURRENCY EXPOSURE AND RISK MANAGEMENT

Mentice uses forward exchange contracts to manage currency risk. Forward exchange contracts are used to hedge risk in connection with accounts receivable and are placed at the time of ordering. Other future cash flows are not hedged. Mentice operations expose it to credit risk when selling to customers. Only advance payments or letters of credit are accepted for sales to new customers or to customers which are deemed to represent a high-risk exposure.

ABOUT THE PARENT COMPANY

Mentice AB (publ.), company registration number 556556-4241, is a Swedish public company with its registered office in Gothenburg, Sweden.

ALTERNATIVE PERFORMANCE MEASURES

Alternative performance measures (APM) are financial measurements that cannot be directly discerned or derived from financial statements. These financial measurements are intended to help the company management and investors to analyze the group's performance. Investors should view these alternative key performance indicators as a complement to the financial statements prepared in accordance with IFRS.

NOTES, CONT.

DEFINITION OF KEY PERFORMANCE INDICATORS REPORTED

Order intake – The value of orders received during the period.

Net sales – sales of products and services are normally recognized in connection with delivery to customer, depending on the terms of delivery. Services, software and projects that run over several periods are recognized as net sales over time.

Order book – Amount of not yet delivered products and services.

Order intake rolling 12 months – Mentice has had recurring growth phases and it is important to view performance over time and not solely for an individual quarter as Mentice historically has had a strong fourth quarter.

Net sales rolling 12 months – Mentice has had recurring growth phases and it is important to view performance over time and not solely for an individual quarter as Mentice historically has had a strong fourth quarter.

Gross profit – Net sales with deduction for cost of goods sold. The indicator shows profitability before fixed costs.

Gross profit margin – Gross profit as a part of net sales. The measure is used to measure operational profitability before fixed costs.

EBITDA – Mentice uses the key performance indicator EBITDA to demonstrate the earning power of the business from operating activities without taking into account the capital structure and tax situation and this is intended to make comparison easier with other companies in the same industry.

EBITDA margin – EBITDA as part of net sales. The measure is used to measure operating profitability, independent of financing, impairment and depreciation.

EBITDA rolling 12 months – Mentice has repeatedly had individual strong quarters, and it is therefore important to continuously see developments over time and not just focus on individual quarters.



FINANCIAL TARGETS, SHORT TO MEDIUM TERM

REVENUE GROWTH

30 – 40% average annual revenue growth during short to medium term (next 3–5 years).

PROFITABILITY

30 % EBITDA margin within short to medium term (3–5 years).

DIVIDEND POLICY

Mentice is a company on a rapidly growing market. In order to capitalise on its market opportunities, the company will prioritise growth, both organic and through acquisitions.

CHANGE IN REPORTING OF NET SALES

A review has been carried out of how our net sales has been distributed between our business areas, geographic markets, and business segments. This review was done based on more consistent analysis and is securing consistency in the numbers. The table named Old reporting show the previous way we reported these sales while the table named New reporting shows the figures after adjustments. Our business segments, we started to report in accordance with IFRS 8 in our annual report 2021, and we have broken out Accessories and spare parts, which earlier was reported as Service. The software development is now a part of Service while it was earlier reported as software licenses. Support as a subscription service is being moved from service to software licenses, recurring. Furthermore, a review has been made of how our metadata connects to the accounting data which is the foundation for the geographic and the business area reporting. This change gives a better possibility to follow our business in a correct way.

OLD REPORTING

TSEK	2020				2021			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
EMEA	16,427	8,842	6,707	10,277	4,207	12,992	9,717	14,885
APAC	9,067	5,245	11,833	11,164	12,049	12,736	10,010	15,765
Americas	8,289	10,260	14,892	24,500	16,060	20,661	18,944	37,038
MDI	20,456	15,848	23,998	27,226	22,123	33,567	31,642	51,828
HCS	7,050	4,698	7,031	16,138	8,847	8,124	5,144	9,461
SA	6,277	3,801	2,403	2,577	1,346	4,698	1,885	6,399
System sales, CAPEX	13,515	9,763	15,834	24,065	15,580	22,427	7,426	33,137
System sales, recurring	470	0	282	1,588	815	1,701	1,789	2,751
Software licenses, CAPEX	8,854	3,553	8,115	7,962	6,274	11,754	8,743	12,985
Software licenses, recurring	4,571	5,025	4,145	5,835	4,249	5,062	3,825	6,130
Accessories and spareparts	541	231	316	1,631	2,828	3,740	4,394	5,873
Service	5,832	5,774	4,741	4,859	2,569	1,705	12,495	6,812

NEW REPORTING

TSEK	2020				2021			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
EMEA	16,171	8,825	7,474	9,370	4,882	12,353	8,668	15,397
APAC	9,154	5,612	8,359	14,184	11,633	13,152	10,011	15,765
Americas	8,454	9,910	17,599	22,387	15,801	20,884	19,992	36,526
MDI	21,683	14,613	25,274	27,586	19,939	35,752	31,641	51,829
HCS	5,531	6,453	6,797	16,138	10,231	6,739	5,145	9,461
SA	6,570	3,281	1,362	2,217	2,150	3,894	1,885	6,398
System sales, CAPEX	13,513	9,768	15,929	23,083	12,871	17,275	16,226	32,027
System sales, recurring	470	-	282	1,588	815	1,701	1,789	2,751
Software licenses, CAPEX	8,853	3,553	8,187	7,654	5,814	12,813	7,197	11,915
Software licenses, recurring	4,571	5,025	4,145	5,835	4,249	5,062	3,825	6,130
Accessories and spareparts	541	231	316	1,631	2,828	3,740	4,394	5,873
Service	5,834	5,770	4,573	6,149	5,742	5,796	5,240	8,993

CHANGE IN REPORTING OF NET SALES

In the annual report of 2021, we defined and started reporting on business segments in accordance with IFRS 8.

Our business segments we started to report in accordance with IFRS 8 in our annual report 2021, and we have broken out Accessories and spare parts which earlier was reported as Service. The software development is now a part of Service while it was earlier reported as software licenses. Support as a subscription service is being moved from service to software licenses, recurring.

FIRST QUARTER 2022

BUSINESS SEGMENTS

TSEK	System sales				Software licenses		Service		Total Group	
	System sales		Accessories & spareparts		Software licenses		Service		2022	2021
	2022	2021	2022	2021	2022	2021	2022	2021		
Sales for capital expenditure	22,972	12,871	5,663	2,828	4,896	5,814	9,004	5,742	42,535	27,255
Recurring revenue	3,380	815	0	0	7,170	4,249	0	0	10,550	5,064
Total	26,352	13,686	5,663	2,828	12,066	10,064	9,004	5,742	53,085	32,320
Raw materials and consumables used	8,019	-4,259	-2,383	-1,956	0	0	-157	-167	-10,559	-6,382
Gross profit	18,333	9,427	3,280	872	12,066	10,064	8,847	5,575	42,526	25,938
Gross profit %	69,6%	68,9%	57,9%	30,8%	100,0%	100,0%	98,3%	97,1%	80,1%	80,3%

FULL YEAR 2021

BUSINESS SEGMENTS

TSEK	System sales				Software licenses		Service		Total Group	
	System sales		Accessories & spareparts		Software licenses		Service		2021	2020
	2021	2020	2021	2020	2021	2020	2021	2020		
Sales for capital expenditure	78,398	62,300	16,834	2,719	31,739	28,246	25,770	22,327	158,741	115,592
Recurring revenue	7,056	2,341	-	-	19,267	19,570	-	-	26,323	21,911
Total	85,454	64,641	16,834	2,719	57,006	47,816	25,770	22,327	185,064	137,503
Raw materials and consumables used	-23,648	-22,227	-7,920	-1,550	0	-378	1,374	-697	-32,942	-24,852
Gross profit	61,806	42,414	8,915	1,169	57,006	47,438	24,396	21,630	152,122	112,651
Gross profit %	72,3%	65,6%	53,0%	43,0%	100,0%	99,2%	94,7%	96,9%	82,2%	81,9%

ABOUT MENTICE



BUSINESS OPERATIONS

Mentice is a company that offers high-technology solutions for simulation to the medical sector with focus on the fast-growing market for endovascular procedures. Mentice's simulators are used to educate, train and improve the practitioners' skills in different types of interventions and when introducing new clinical instruments. The company offers "flight simulations" for physicians and clinical teams to provide practitioners with experiences as realistic as possible. Headquartered in Gothenburg, Sweden. Mentice has a strong global presence with companies established in the US, Japan and China.

BUSINESS IDEA

Mentice business idea is to assist in the aim to reduce deaths, injuries and costs resulting from medical errors and inefficiencies and ultimately to reduce risk of harm to patients. By developing and providing innovative and realistic training tools, the company will help to improve the clinical skills of doctors and reduce the risk of needless errors. Medical errors are a major problem for society that come at a large cost and are the third most common cause of death in the USA, behind heart disease and cancer. Close integration with health service and the rest of the medical device industry is vital to promote innovative solutions that enhance the simulation experience.

Sustainability, social and environmental issues are a core element of Mentice code of conduct and its operations. Mentice has a strong focus on the continuing innovation of the products it offers and on taking simulation to new heights to offer the best possible solutions for customers at hospitals, clinics, universities and in research groups as well as in the medical device industry. The company has clear ambitions and principles to take economic, social, and environmental responsibility.

PURPOSE

Mentice's purpose is to reduce deaths, injuries and costs resulting from medical errors and inefficiencies by developing innovative and inspirational tools for the improvement of clinical skills.

VISION


Mentice's vision is to lead endovascular care to the highest standards of patient safety and performance.

MISSION

We believe medical technology helps to improve patient outcomes and clinical performance. Our mission is to improve operational efficiency and patient outcomes by introducing innovative solutions that eliminate proficiency barriers.

OUR RESULTS ARE GLOBAL

PROUD TO BE TRUSTED BY ORGANIZATIONS WORLDWIDE



YEARS OF EXPERIENCE
PIONEERING INTERVENTIONAL
SIMULATION.



OVER 140 SCIENTIFIC
PAPERS REINFORCING THE
VALUE OF SIMULATION SKILLS
ACQUISITION, RETENTION
AND ASSESSMENT.



MEDICAL SIMULATION
PATENTS ACROSS MORE
THAN 30 DIFFERENT
TRAINING PROCEDURES



OF GLOBAL MARKET
SHARE IN ENDOVASCULAR
SIMULATION SOLUTIONS.

FINANCIAL CALENDAR

ANNUAL REPORT 2022
INTERIM REPORT JAN-MAR 2023
ANNUAL GENERAL MEETING
INTERIM REPORT APR-JUN 2023
INTERIM REPORT JUL-SEP 2023

APRIL 6, 2023
APRIL 27, 2023
MAY 11, 2023
JULY 20, 2023
OCTOBER 26, 2023

Mentice's interim reports and annual reports are available on www.mentice.com

